Founded in 1984, Bain Capital is an alternative investment firm. They manage $105 billion in assets across their eighteen global locations. Their Bain Capital Life Sciences is a venture capital fund which specializes in buyouts, inflection capital, growth capital, turnaround and private equity investments in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and life science technology sectors.
Bain Capital Life Science was initially raised in May 2017 at $720 million.
Bain Capital Life Sciences has invested in Annexon Biosciences, Aptinyx, Arcutis Biotherapeutics, Cerevel Therapeuticvs, Constellation Pharmaceuticals, Dicerna Pharmaceuticals Inc., Gynesonics, Hugel, InlfaRx, Kestra Medical Technologies, Marinus Pharmaceuticals, Rapid Micro Biosystems, Replimune, SpringWorks Therapeutics, Solid Biosciences and ViaCyte.
ViaCyte is a biotechnology company using stem cells to create pancreatic beta cell precursors for treating diabetes.
A biotechnology company the develops tools for detection of microbial contamination
SpringWorks Therapeutics is a Stamford, Connecticut-based company.
Solid Biosciences is a Cambridge, Massachusetts-based biotechnology company.
Gynesonics is a Redwood City, California-based healthcare company.